[28] [29] However, there is currently no robust clinical trial evidence specifically examining GLP-1 medications for hot flash management, and no official link has been established between GLP-1 therapy and vasomotor symptom improvement
It is a spectrum
However, caution should be taken when interpreting these results due to short follow-up periods (i.e., 1.11.4 years [18,19,20]), the possibility of confounding bias caused by the inclusion of advanced T2D cases (i.e., requiring intensive insulin therapy [18]), uncertain liver effects (e.g., incident NAFLD) of active comparators (i.e., DPP4is [19, 20] and insulin [18]), lack of dose-response analysis, and limited generalizability to other ethnic populations
In 2023 Lilly published results of its phase 2 trial for orforglipron, a once-daily oral drug which achieved up to 14.7% mean weight reduction at 36 weeks, and Pfizer has completed phase 2 trial for its oral drug danuglipron and is now optimising the formulation
If the coldness is persistent, severe, or accompanied by other symptoms, it is worth a conversation with your physician
The changes of cellular impedance induced by a second addition were measured over 10 min
